On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation

被引：123
作者：
Lesokhin, Alexander M. [1 ,2 ]
Callahan, Margaret K. [1 ,2 ]
Postow, Michael A. [1 ,2 ]
Wolchok, Jedd D. [1 ,2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA
[2] Weill Cornell Med Coll, New York, NY 10065 USA
来源：
SCIENCE TRANSLATIONAL MEDICINE | 2015年 / 7卷 / 280期
关键词：
ANTI-CD40; MONOCLONAL-ANTIBODY; ADVANCED MELANOMA PATIENTS; PHASE-I; CTLA-4; BLOCKADE; REGULATORY T; AUTOIMMUNE HYPOPHYSITIS; CLINICAL ACTIVITY; SOLID TUMORS; METASTATIC MELANOMA; ANTI-PD-L1; ANTIBODY;
D O I：
10.1126/scitranslmed.3010274
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
The recent approvals of two drugs that block the function of the immune checkpoint programmed cell death 1 (PD-1) have firmly planted tumor immunotherapy in the mainstream of clinical oncology. We provide a historical and immunologic context for these recent advances and discuss translational studies that provide insight into the efficacy of cancer immunotherapy at the individual patient level.
引用
收藏
页数：12
相关论文
共 145 条
[1]   Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma [J].
Advani, Ranjana ;
Forero-Torres, Andres ;
Furman, Richard R. ;
Rosenblatt, Joseph D. ;
Younes, Anas ;
Ren, Hong ;
Harrop, Kate ;
Whiting, Nancy ;
Drachman, Jonathan G. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) :4371-4377
[2]  
Andrews Stephanie, 2012, Cancer Manag Res, V4, P299, DOI 10.2147/CMAR.S31873
[3]  
[Anonymous], 2006, J CLIN ONCOL
[4]  
[Anonymous], J CLIN ONCOL S5S
[5]  
Ansell S. M., 2014, ASCO M, V32
[6]   PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].
Ansell, Stephen M. ;
Lesokhin, Alexander M. ;
Borrello, Ivan ;
Halwani, Ahmad ;
Scott, Emma C. ;
Gutierrez, Martin ;
Schuster, Stephen J. ;
Millenson, Michael M. ;
Cattry, Deepika ;
Freeman, Gordon J. ;
Rodig, Scott J. ;
Chapuy, Bjoern ;
Ligon, Azra H. ;
Zhu, Lili ;
Grosso, Joseph F. ;
Kim, Su Young ;
Timmerman, John M. ;
Shipp, Margaret A. ;
Armand, Philippe .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319
[7]   Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma [J].
Ansell, Stephen M. ;
Hurvitz, Sara A. ;
Koenig, Patricia A. ;
LaPlant, Betsy R. ;
Kabat, Brian F. ;
Fernando, Donna ;
Habermann, Thomas M. ;
Inwards, David J. ;
Verma, Meena ;
Yamada, Reiko ;
Erlichman, Charles ;
Lowy, Israel ;
Timmerman, John M. .
CLINICAL CANCER RESEARCH, 2009, 15 (20) :6446-6453
[8]   Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial [J].
Armand, Philippe ;
Nagler, Arnon ;
Weller, Edie A. ;
Devine, Steven M. ;
Avigan, David E. ;
Chen, Yi-Bin ;
Kaminski, Mark S. ;
Holland, H. Kent ;
Winter, Jane N. ;
Mason, James R. ;
Fay, Joseph W. ;
Rizzieri, David A. ;
Hosing, Chitra M. ;
Ball, Edward D. ;
Uberti, Joseph P. ;
Lazarus, Hillard M. ;
Mapara, Markus Y. ;
Gregory, Stephanie A. ;
Timmerman, John M. ;
Andorsky, David ;
Or, Reuven ;
Waller, Edmund K. ;
Rotem-Yehudar, Rinat ;
Gordon, Leo I. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (33) :4199-4206
[9]   High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].
Atkins, MB ;
Lotze, MT ;
Dutcher, JP ;
Fisher, RI ;
Weiss, G ;
Margolin, K ;
Abrams, J ;
Sznol, M ;
Parkinson, D ;
Hawkins, M ;
Paradise, C ;
Kunkel, L ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116
[10]   Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma [J].
Barker, Christopher A. ;
Postow, Michael A. ;
Khan, Shaheer A. ;
Beal, Kathryn ;
Parhar, Preeti K. ;
Yamada, Yoshiya ;
Lee, Nancy Y. ;
Wolchok, Jedd D. .
CANCER IMMUNOLOGY RESEARCH, 2013, 1 (02) :92-98
12345678910